Human medicines European public assessment report (EPAR): Welireg, belzutifan, Date of authorisation: 12/02/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Mavenclad, cladribine, Date of authorisation: 22/08/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Kisunla, donanemab, Date of authorisation: 24/09/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Yesintek, ustekinumab, Date of authorisation: 14/02/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Besremi, ropeginterferon alfa-2b, Date of authorisation: 15/02/2019, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Inrebic, fedratinib, Date of authorisation: 08/02/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): GalenVita, germanium (68Ge) chloride,gallium (68Ga) chloride, Date of authorisation: 08/01/2026, Status: Authorised

Dates of 2026 Scientific Advice Working Party - Human (SAWP-H) meetings and submission deadlines for scientific advice, protocol assistance, qualification of novel methodologies and HTACG/EMA parallel Joint Scientific Consultation (JSC) requests

Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Date of authorisation: 17/10/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Voydeya, danicopan, Date of authorisation: 19/04/2024, Revision: 3, Status: Authorised